Formosa Pharmaceuticals and the Singapore Eye Research Institute (SERI) have announced a research collaboration to develop next-generation ophthalmic formulations. This partnership will leverage Formosa’s proprietary Active Pharmaceutical (ingredient) Nanoparticle Technology (APNT) and SERI’s world-class clinical research expertise, led by clinician scientist, Associate Professor Yu-Chi Liu, MD, PhD.

The collaboration aims to address significant unmet needs in the treatment of corneal and ocular surface diseases. By combining innovative and clinically validated drug delivery platforms with deep clinical insights, the joint effort seeks to enhance the efficacy, bioavailability, and safety of topical ocular therapies, bringing new therapies to clinical practice.

Prof Liu brings extensive experience in corneal neuropathy and translational medicine to the collaboration. Her recent work in diabetic keratopathy and ocular surface inflammation will be pivotal in guiding the development of formulations targeting complex anterior segment conditions.

Prof. Liu said, “Collaborating with Formosa Pharmaceuticals allows us to bridge the gap between benchside innovation and bedside application. Our goal is to utilise advanced formulation technologies like APNT to create treatments that are not only more effective but also less burdensome for patients suffering from ocular conditions.”